Alzheimer's disease and type 2 diabetes—hope for inhibitors against amyloid plaques

August 8, 2018, Technical University Munich
A new class of designed macrocyclic peptides has been developed which are highly potent inhibitors of amyloid plaque formation. Credit: Kapurniotu/ TUM

Effective therapeutics to counteract the formation of amyloid plaques in Alzheimer's disease and type 2 diabetes are not yet available. Scientists at the Technical University of Munich (TUM) have now come a little bit closer to a solution: They have described a new class of designed macrocyclic peptides that are highly potent inhibitors of amyloid formation.

Amyloid plaques, which are protein deposits, play a crucial role in the development of Alzheimer's disease and type 2 diabetes. Several teams of scientists around the world are working on finding ways to prevent amyloid plaque formation in the human brain.

The research team of Aphrodite Kapurniotu, Professor for Peptide Biochemistry (TUM) has been working on an idea for some time now in collaboration with the teams of Professor Martin Zacharias (TUM), Professor Gerhard Rammes (TUM Rechts der Isar Hospital) and Professor Jürgen Bernhagen (Institute for Stroke and Dementia Research (ISD) at Ludwig Maximilian University (LMU)). The researchers have presented (MCIPs) as of . They reported their results in the journal Angewandte Chemie.

New class of amyloid inhibitors

In its new study, the team presents macrocyclic peptides, developed as a new class of amyloid inhibitors. "We have discovered an MCIP that is stable in human blood plasma and can also overcome the human blood-brain barrier in an in vitro cell culture model," explains Professor Kapurniotu. She adds, "So far we were only able to demonstrate these properties in the test tube—thus, further research is necessary. But these are two highly desirable properties for inhibitors of Alzheimer's amyloid."

TUM has already applied for a patent for the newly developed macrocyclic peptides. "They could be a good alternative to the currently pursued antibody-based approaches as therapeutics against Alzheimer's because they are easy to produce, have promising properties and, due to their peptidic nature, they will be significantly cheaper than antibodies," says Professor Kapurniotu.

"Therefore, further investigations are now planned to verify whether the MCIPs are also effective in in vivo models. Furthermore, the MCIPs could also be suitable as templates for the development of small molecule peptidomimetics (molecules mimicking peptide chains), which might also find application as anti- drugs in Alzheimer's and type 2 diabetes.

Explore further: Amyloid plaques in Alzheimer's and diabetes: Novel leads for inhibitors

More information: Anna Spanopoulou et al, Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements, Angewandte Chemie International Edition (2018). DOI: 10.1002/anie.201802979

Related Stories

Amyloid plaques in Alzheimer's and diabetes: Novel leads for inhibitors

September 24, 2015
When proteins change their structure and clump together, formation of amyloid fibrils and plaques may occur. Such 'misfolding' and 'protein aggregation' processes damage cells and cause diseases such as Alzheimer's and type ...

Researchers discover insights into amyloids associated with Alzheimer's and type 2 diabetes

June 26, 2018
A Virginia Tech research team has discovered insights into the stabilizing forces of amyloid fibrils that are associated with Alzheimer's disease and type 2 diabetes.

Mutation discovered to protect against Alzheimer's disease in mice

May 16, 2018
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific ...

Brain cholesterol associated with increased risk of Alzheimer's disease

May 7, 2018
Researchers have shown how cholesterol—a molecule normally linked with cardiovascular diseases—may also play an important role in the onset and progression of Alzheimer's disease.

Structural analysis of relevant drug targets for Alzheimer's disease

June 12, 2017
Alzheimer's Disease (AD) is classified as a neurodegenerative non-curable disease that affects millions worldwide. Current drugs have side effects that are significant. In AD, the beta-amyloid precursor protein (β-APP) that ...

Recommended for you

Hypothesis underpinning dementia research 'flawed'

October 16, 2018
A hypothesis which has been the standard way of explaining how the body develops Alzheimer's Disease for almost 30 years is flawed, according to a University of Manchester biologist.

Study suggests biological basis for depression, anxiety, sleep disturbances in older adults

October 15, 2018
UC San Francisco researchers, in collaboration with the unique Brazilian Biobank for Aging Studies (BBAS) at the University of São Paulo, have shown that the earliest stages of the brain degeneration associated with Alzheimer's ...

Many cases of dementia may arise from non-inherited DNA 'spelling mistakes'

October 15, 2018
Only a small proportion of cases of dementia are thought to be inherited—the cause of the vast majority is unknown. Now, in a study published today in the journal Nature Communications, a team of scientists led by researchers ...

Scientists create new map of brain region linked to Alzheimer's disease

October 8, 2018
Curing some of the most vexing diseases first requires navigating the world's most complex structure—the human brain. So, USC scientists have created the most detailed atlas yet of the brain's memory bank.

Previously unknown genetic aberrations found to be associated with Alzheimer's progression

October 8, 2018
In a large-scale analysis of RNA from postmortem human brain tissue, researchers at the Icahn School of Medicine at Mount Sinai and Columbia University have identified specific RNA splicing events associated with Alzheimer's ...

Periodontal disease bacteria may kick-start Alzheimer's

October 4, 2018
Long-term exposure to periodontal disease bacteria causes inflammation and degeneration of brain neurons in mice that is similar to the effects of Alzheimer's disease in humans, according to a new study from researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.